Peter Stopfer
- Oncology top 2%
- HER2/EGFR in Cancer Research 19
- Drug Transport and Resistance Mechanisms 13
- Colorectal Cancer Treatments and Studies 9
-
- Lung Cancer Treatments and Mutations 29
- Pharmacology top 2%
- Pharmacogenetics and Drug Metabolism 8
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis 9
- Genetics top 10%
-
- Pharmacological Effects and Toxicity Studies 9
-
- Angiogenesis and VEGF in Cancer 8
- Co-authors
- Thomas EbnerSven WindR. KaiserKristell MarzinMatthias FreiwaldDietmar GanßerMartina Uttenreuther‐FischerMehdi Shahidi
- Journals
- Journal of Clinical Oncology (14 papers)Clinical Pharmacokinetics (5 papers)Annals of Oncology (4 papers)
- Partner nations
- GermanyUnited StatesFrance
In The Last Decade
Peter Stopfer
68 papers receiving 2.6k citations
Peers
Comparison fields: 5 of 97
- Oncology 1.5k
- Pulmonary and Respiratory Medicine 1.4k
- Pharmacology 178
- Hepatology 150
- Genetics 159
Countries citing papers authored by Peter Stopfer
This map shows the geographic impact of Peter Stopfer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Stopfer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Stopfer more than expected).
Fields of papers citing papers by Peter Stopfer
This network shows the impact of papers produced by Peter Stopfer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Stopfer. The network helps show where Peter Stopfer may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Peter Stopfer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 5 | |
| 5 | 2023 | 13 | |
| 6 | 2023 | 15 | |
| 7 | 2020 | 45 | |
| 8 | 2019 | 138 | |
| 9 | 2016 | 146 | |
| 10 | 2014 | 12 | |
| 11 | 2014 | 26 | |
| 12 | 2012 | 39 | |
| 13 | 2012 | 31 | |
| 14 | 2011 | 11 | |
| 15 | 2010 | 295 | |
| 16 | 2007 | 202 | |
| 17 | 2007 | 10 | |
| 18 | 2007 | 23 | |
| 19 | Pharmacokinetic results from two phase I dose escalation studies of once daily oral treatment with BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. | 2005 | 6 |
| 20 | 2004 | 58 |
About Peter Stopfer
Peter Stopfer is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Hepatology, Pharmacology and Cancer Research, having authored 69 papers that have together received 2.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (29 papers), HER2/EGFR in Cancer Research (19 papers), Drug Transport and Resistance Mechanisms (13 papers), Hepatocellular Carcinoma Treatment and Prognosis (9 papers), Colorectal Cancer Treatments and Studies (9 papers), Pharmacological Effects and Toxicity Studies (9 papers), Pharmacogenetics and Drug Metabolism (8 papers) and Angiogenesis and VEGF in Cancer (8 papers). The work is most often cited by research in Oncology (1.5k citations), Pulmonary and Respiratory Medicine (1.4k citations), Pharmacology (178 citations), Hepatology (150 citations) and Genetics (159 citations). Peter Stopfer has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Thomas Ebner, Sven Wind, R. Kaiser, Kristell Marzin, Matthias Freiwald, Dietmar Ganßer, Martina Uttenreuther‐Fischer, Mehdi Shahidi, Thomas Hehlgans and Martin Štefanič. Their work appears in journals such as Journal of Clinical Oncology, Clinical Pharmacokinetics, Annals of Oncology, Clinical Pharmacology & Therapeutics and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.